INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...

Eli Lilly LLY announced that the phase IV CHALLENGE-MIG study, evaluating the efficacy and safety of its migraine drug Emgality against Pfizer‘s PFE Nurtec ODT, failed to meet primary endpoint of ...

The first and only anti-CGRP treatment with dual indications TORONTO, Feb. 25, 2021 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce that Emgality® (galcanezumab) is now indicated ...

As Biohaven’s fast-growing Nurtec ODT pressures rival migraine prevention medicines, one injectable player decided to bring the fight directly to the oral drug with a head-to-head clinical trial. Eli ...

The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...

If Eli Lilly and Co. had been hoping its migraine drug, Emgality (galcanezumab), would emerge with unequivocal superiority against Pfizer Inc.’s Nurtec ODT (rimegepant orally disintegrating tablet), ...